Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) – Pipeline Review, H2 2016’, provides in depth analysis on Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted pipeline therapeutics.

The report provides comprehensive information on the Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)

The report reviews Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects

The report assesses Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Acetylon Pharmaceuticals, Inc.

Chong Kun Dang Pharmaceutical Corp.

Curis, Inc.

HitGen LTD

Kancera AB

Karus Therapeutics Limited

Lycera Corp.

Merck & Co., Inc.

Millennium Pharmaceuticals Inc

OncoHoldings, Inc.

OnKure Inc

Quimatryx, S.L.

Sigma-Tau S.p.A.

SK Biopharmaceuticals Co., Ltd.

Takeda Pharmaceutical Company Limited

TetraLogic Pharmaceuticals

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC

3.5.1.98) Overview 10

Therapeutics Development 11

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC

3.5.1.98) - Products under Development by Stage of Development 11

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC

3.5.1.98) - Products under Development by Therapy Area 12

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC

3.5.1.98) - Products under Development by Indication 13

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC

3.5.1.98) - Pipeline Products Glance 16

Late Stage Products 16

Early Stage Products 17

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC

3.5.1.98) - Products under Development by Companies 18

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC

3.5.1.98) - Products under Development by Universities/Institutes 24

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC

3.5.1.98) - Therapeutics Assessment 26

Assessment by Monotherapy/Combination Products 26

Assessment by Mechanism of Action 27

Assessment by Route of Administration 28

Assessment by Molecule Type 30

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC

3.5.1.98) - Companies Involved in Therapeutics Development 32

Acetylon Pharmaceuticals, Inc. 32

Chong Kun Dang Pharmaceutical Corp. 34

Curis, Inc. 35

HitGen LTD 36

Kancera AB 37

Karus Therapeutics Limited 38

Lycera Corp. 39

Merck & Co., Inc. 40

Millennium Pharmaceuticals Inc 41

OncoHoldings, Inc. 42

OnKure Inc 43

Quimatryx, S.L. 44

Sigma-Tau S.p.A. 45

SK Biopharmaceuticals Co., Ltd. 46

Takeda Pharmaceutical Company Limited 47

TetraLogic Pharmaceuticals 48

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC

3.5.1.98) - Drug Profiles 49

ACY-738 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

ACY-775 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

C-1A - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

citarinostat - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

CKD-504 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

CKD-506 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

CKD-L - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

CUDC-907 - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

HG-3001 - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

IKH-12 - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

KA-2507 - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

KAN-0439221 - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

KAN-0439782 - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

KAR-3000 - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

MPT-0B291 - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

N-140 - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

Nexturastat A - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

ONCO-101 - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

QTX-100 Series - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

QTX-102 - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

QTX-125 - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

QTX-153 - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

remetinostat - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

ricolinostat - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

Small Molecule to HDAC6 HDAC6 for Sepsis - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma - Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

Small Molecule to Inhibit HDAC6 - Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

Small Molecule to Inhibit HDAC6 for Charcot-Marie-Tooth Disease - Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

Small Molecule to Inhibit HDAC6 for Oncology - Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

Small Molecules to Inhibit HDAC-6 for Immunology, Oncology and Genetic Disorders - Drug Profile 91

Product Description 91

Mechanism Of Action 91

R&D Progress 91

Small Molecules to Inhibit HDAC6 for Autoimmune Diseases - Drug Profile 92

Product Description 92

Mechanism Of Action 92

R&D Progress 92

Small Molecules to Inhibit HDAC6 for Neurodegenerative, Autoimmune and Inflammatory Diseases - Drug Profile 93

Product Description 93

Mechanism Of Action 93

R&D Progress 93

Small Molecules to Inhibit HDAC6 for Oncology - Drug Profile 94

Product Description 94

Mechanism Of Action 94

R&D Progress 94

Small Molecules to Inhibit HDAC6 for Oncology and Immunology - Drug Profile 95

Product Description 95

Mechanism Of Action 95

R&D Progress 95

Small Molecules to Inhibit Histone Deacetylase 6 for Oncology - Drug Profile 96

Product Description 96

Mechanism Of Action 96

R&D Progress 96

ST-3595 - Drug Profile 97

Product Description 97

Mechanism Of Action 97

R&D Progress 97

Synthetic Peptides to Inhibit HDAC6 for Oncology - Drug Profile 98

Product Description 98

Mechanism Of Action 98

R&D Progress 98

vorinostat - Drug Profile 99

Product Description 99

Mechanism Of Action 99

R&D Progress 99

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC

3.5.1.98) - Dormant Projects 103

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC

3.5.1.98) - Featured News & Press Releases 106

Jun 13, 2016: Acetylon Presents Data on the Use of HDAC6 Inhibitor Ricolinostat (ACY-1215) in Combination with Pomalidomide and Dexamethasone for the Treatment of Multiple Myeloma 106

Jun 13, 2016: Acetylon Presents Data on the Use of HDAC6 Inhibitor ACY-241 in Combination with Pomalidomide and Dexamethasone for the Treatment of Multiple Myeloma 107

Jun 08, 2016: Curis Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association 107

Jun 03, 2016: Acetylon Collaborators Publish ASCO Abstracts Demonstrating Immunomodulatory Properties of Ricolinostat in Preclinical Melanoma Models 108

Jun 02, 2016: Curis Announces Presentations Related to CUDC-907 at 2016 ASCO Annual Meeting 109

Apr 20, 2016: Acetylon Announces the Presentation of Preclinical Data at AACR Supporting the Use of Selective HDAC6 Inhibition to Modulate Chronic Lymphocytic Leukemia (CLL) Immunobiology 109

Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CUDC-907 at AACR Annual Meeting 111

Apr 04, 2016: Curis Announces Publication of CUDC-907 Phase 1 Clinical Trial Data in Lancet Oncology 111

Dec 07, 2015: Acetylon Presents Data from Three Phase 1b Studies of Ricolinostat (ACY-1215) for the Treatment of Lymphoma and Multiple Myeloma 111

Dec 07, 2015: Acetylon Presents Data on the use of HDAC 6 Inhibitors Ricolinostat and ACY-241 in Combination with Pomalidomide for the Treatment of Multiple Myeloma 113

Dec 06, 2015: Curis Reports Clinical Activity of CUDC-907 in Patients With DLBCL Harboring MYC Oncogene Alterations at the 2015 ASH Annual Meeting 115

Nov 06, 2015: Acetylon's Oral Selective HDAC6 Inhibitor ACY-241 Enhances Anti-tumor Activity of Paclitaxel in Preclinical Solid Tumor Models 117

Nov 05, 2015: Curis Announces Oral Presentation of Phase 1 Data for CUDC-907 at 2015 ASH Annual Meeting 118

Nov 02, 2015: TetraLogic Announces the Opening of an IND for SHAPE Gel in Alopecia Areata 119

Jun 15, 2015: Acetylon Pharmaceuticals Presented Positive Preliminary Data from Phase 1b/2 Trial of Ricolinostat in Combination with Pomalyst as Potential Oral Treatment for Patients with Multiple Myeloma 119

Appendix 122

Methodology 122

Coverage 122

Secondary Research 122

Primary Research 122

Expert Panel Validation 122

Contact Us 122

Disclaimer 123

List of Tables

List of Tables

Number of Products under Development for, H2 2016 11

Number of Products under Development by Therapy Area, H2 2016 12

Number of Products under Development by Indication, H2 2016 14

Comparative Analysis by Late Stage Development, H2 2016 16

Comparative Analysis by Early Stage Products, H2 2016 17

Number of Products under Development by Companies, H2 2016 18

Products under Development by Companies, H2 2016 19

Products under Development by Companies, H2 2016 (Contd..1) 20

Products under Development by Companies, H2 2016 (Contd..2) 21

Products under Development by Companies, H2 2016 (Contd..3) 22

Products under Development by Companies, H2 2016 (Contd..4) 23

Number of Products under Investigation by Universities/Institutes, H2 2016 24

Products under Investigation by Universities/Institutes, H2 2016 25

Assessment by Monotherapy/Combination Products, H2 2016 26

Number of Products by Stage and Mechanism of Action, H2 2016 27

Number of Products by Stage and Route of Administration, H2 2016 29

Number of Products by Stage and Molecule Type, H2 2016 31

Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016 32

Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016 34

Pipeline by Curis, Inc., H2 2016 35

Pipeline by HitGen LTD, H2 2016 36

Pipeline by Kancera AB, H2 2016 37

Pipeline by Karus Therapeutics Limited, H2 2016 38

Pipeline by Lycera Corp., H2 2016 39

Pipeline by Merck & Co., Inc., H2 2016 40

Pipeline by Millennium Pharmaceuticals Inc, H2 2016 41

Pipeline by OncoHoldings, Inc., H2 2016 42

Pipeline by OnKure Inc, H2 2016 43

Pipeline by Quimatryx, S.L., H2 2016 44

Pipeline by Sigma-Tau S.p.A., H2 2016 45

Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016 46

Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 47

Pipeline by TetraLogic Pharmaceuticals, H2 2016 48

Dormant Projects, H2 2016 103

Dormant Projects (Contd..1), H2 2016 104

Dormant Projects (Contd..2), H2 2016 105

List of Figures

List of Figures

Number of Products under Development for, H2 2016 11

Number of Products under Development by Therapy Area, H2 2016 12

Number of Products under Development by Top 10 Indication, H2 2016 13

Comparative Analysis by Late Stage Development, H2 2016 16

Comparative Analysis by Early Stage Products, H2 2016 17

Assessment by Monotherapy/Combination Products, H2 2016 26

Number of Products by Stage and Mechanism of Actions, H2 2016 27

Number of Products by Routes of Administration, H2 2016 28

Number of Products by Stage and Routes of Administration, H2 2016 28

Number of Products by Molecule Types, H2 2016 30

Number of Products by Stage and Molecule Type, H2 2016 30

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports